JWCTF Financial Statements From 2010 to 2025
| JWCTF Stock | USD 0.36 0.03 7.69% |
Check JW (Cayman) financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among JW (Cayman)'s main balance sheet or income statement drivers, such as , as well as many indicators such as . JWCTF financial statements analysis is a perfect complement when working with JW (Cayman) Valuation or Volatility modules.
JWCTF |
JW Therapeutics Co Company Return On Asset Analysis
JW (Cayman)'s Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current JW (Cayman) Return On Asset | -0.15 |
Most of JW (Cayman)'s fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, JW Therapeutics Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, JW Therapeutics Co has a Return On Asset of -0.1528. This is 98.25% lower than that of the Healthcare sector and 99.35% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 9.14% higher than that of the company.
JW Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining JW (Cayman)'s current stock value. Our valuation model uses many indicators to compare JW (Cayman) value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across JW (Cayman) competition to find correlations between indicators driving JW (Cayman)'s intrinsic value. More Info.JW Therapeutics Co is rated fifth overall in return on equity category among its peers. It also is rated fifth overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the JW (Cayman)'s earnings, one of the primary drivers of an investment's value.About JW (Cayman) Financial Statements
JW (Cayman) stakeholders use historical fundamental indicators, such as JW (Cayman)'s revenue or net income, to determine how well the company is positioned to perform in the future. Although JW (Cayman) investors may analyze each financial statement separately, they are all interrelated. For example, changes in JW (Cayman)'s assets and liabilities are reflected in the revenues and expenses on JW (Cayman)'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in JW Therapeutics Co. Please read more on our technical analysis and fundamental analysis pages.
Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. Ltd was founded in 2016 and is headquartered in Shanghai, the Peoples Republic of China. Jw Cayman is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in JWCTF Pink Sheet
JW (Cayman) financial ratios help investors to determine whether JWCTF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in JWCTF with respect to the benefits of owning JW (Cayman) security.